ARTICLE | Strategy
Warp's independence day
Why Warp, Sanofi reworked their build-to-buy partnership into a licensing deal
January 18, 2016 8:00 AM UTC
New revelations about the breadth of Warp Drive Bio LLC's platform, coupled with the lengthy biotech boom, led the company and partner Sanofi to toss out their 2012 build-to-buy deal in favor of a traditional licensing agreement. Sanofi felt the biotech could do a better job of prosecuting the platform as an independent company, increasing the potential value of the pharma's 50% stake.
Warp, meanwhile, gets the freedom to work with other partners or keep programs for itself...